• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022

    11/8/22 9:43:36 AM ET
    $ACA
    $ADNT
    $ASML
    $AVEO
    Metal Fabrications
    Industrials
    Auto Parts:O.E.M.
    Consumer Discretionary
    Get the next $ACA alert in real time by email

    Upgrades

    • For SolarEdge Technologies Inc (NASDAQ:SEDG), Northland Capital Markets upgraded the previous rating of Underperform to Market Perform. In the third quarter, SolarEdge Technologies showed an EPS of $0.91, compared to $1.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of $375.90 and a 52-week-low of $190.15. SolarEdge Technologies closed at $211.30 at the end of the last trading period.
    • According to Scotiabank, the prior rating for Delek US Holdings Inc (NYSE:DK) was changed from Sector Underperform to Sector Perform. Delek US Hldgs earned $0.02 in the third quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $35.23 and a 52-week-low of $14.71. At the end of the last trading period, Delek US Hldgs closed at $33.62.
    • According to William Blair, the prior rating for Stratasys Ltd (NASDAQ:SSYS) was changed from Underperform to Market Perform. Stratasys earned $0.02 in the second quarter, compared to $0.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of $28.00 and a 52-week-low of $12.69. Stratasys closed at $13.67 at the end of the last trading period.
    • According to Goldman Sachs, the prior rating for Mettler-Toledo International Inc (NYSE:MTD) was changed from Sell to Neutral. Mettler-Toledo Intl earned $10.18 in the third quarter, compared to $8.72 in the year-ago quarter. The current stock performance of Mettler-Toledo Intl shows a 52-week-high of $1699.11 and a 52-week-low of $1065.55. Moreover, at the end of the last trading period, the closing price was at $1298.71.
    • Morgan Stanley upgraded the previous rating for Southern Copper Corp (NYSE:SCCO) from Equal-Weight to Overweight. Southern Copper earned $0.56 in the second quarter, compared to $1.21 in the year-ago quarter. At the moment, the stock has a 52-week-high of $79.31 and a 52-week-low of $42.42. Southern Copper closed at $53.04 at the end of the last trading period.
    • According to Deutsche Bank, the prior rating for Dave & Buster's Entertainment Inc (NASDAQ:PLAY) was changed from Hold to Buy. For the second quarter, Dave & Buster's Enter had an EPS of $0.64, compared to year-ago quarter EPS of $1.07. The current stock performance of Dave & Buster's Enter shows a 52-week-high of $52.54 and a 52-week-low of $29.60. Moreover, at the end of the last trading period, the closing price was at $37.05.
    • Piper Sandler upgraded the previous rating for 2U Inc (NASDAQ:TWOU) from Underweight to Neutral. For the third quarter, 2U had an EPS of $0.05, compared to year-ago quarter EPS of $0.23. The stock has a 52-week-high of $20.98 and a 52-week-low of $4.70. At the end of the last trading period, 2U closed at $6.36.
    • According to Macquarie, the prior rating for Block Inc (NYSE:SQ) was changed from Neutral to Outperform. For the third quarter, Block had an EPS of $0.42, compared to year-ago quarter EPS of $0.37. At the moment, the stock has a 52-week-high of $165.20 and a 52-week-low of $51.34. Block closed at $62.67 at the end of the last trading period.
    • For Viatris Inc (NASDAQ:VTRS), Piper Sandler upgraded the previous rating of Underweight to Neutral. Viatris earned $0.87 in the third quarter, compared to $0.99 in the year-ago quarter. At the moment, the stock has a 52-week-high of $15.60 and a 52-week-low of $8.42. Viatris closed at $10.97 at the end of the last trading period.
    • According to Stifel, the prior rating for Global Partners LP (NYSE:GLP) was changed from Hold to Buy. In the third quarter, Global Partners showed an EPS of $3.12, compared to $0.86 from the year-ago quarter. At the moment, the stock has a 52-week-high of $35.29 and a 52-week-low of $20.23. Global Partners closed at $29.96 at the end of the last trading period.
    • According to Barclays, the prior rating for The Scotts Miracle Gro Co (NYSE:SMG) was changed from Equal-Weight to Overweight. Scotts Miracle Gro earned $2.04 in the fourth quarter, compared to $0.82 in the year-ago quarter. At the moment, the stock has a 52-week-high of $167.09 and a 52-week-low of $39.05. Scotts Miracle Gro closed at $51.71 at the end of the last trading period.

    See all analyst ratings upgrades.

     

    Downgrades

    • For Huntsman Corp (NYSE:HUN), Tudor Pickering downgraded the previous rating of Buy to Hold. Huntsman earned $0.71 in the third quarter, compared to $1.08 in the year-ago quarter. The current stock performance of Huntsman shows a 52-week-high of $41.65 and a 52-week-low of $23.54. Moreover, at the end of the last trading period, the closing price was at $26.72.
    • Wolfe Research downgraded the previous rating for JELD-WEN Holding Inc (NYSE:JELD) from Peer Perform to Underperform. JELD-WEN Holding earned $0.71 in the third quarter, compared to $0.45 in the year-ago quarter. The stock has a 52-week-high of $27.59 and a 52-week-low of $8.38. At the end of the last trading period, JELD-WEN Holding closed at $9.46.
    • Truist Securities downgraded the previous rating for WM Technology Inc (NASDAQ:MAPS) from Buy to Hold. WM Tech earned $0.06 in the third quarter, compared to $0.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of $8.35 and a 52-week-low of $1.58. WM Tech closed at $1.93 at the end of the last trading period.
    • For Marsh & McLennan Companies Inc (NYSE:MMC), Atlantic Equities downgraded the previous rating of Overweight to Neutral. In the third quarter, Marsh & McLennan showed an EPS of $1.18, compared to $1.08 from the year-ago quarter. The stock has a 52-week-high of $183.14 and a 52-week-low of $142.80. At the end of the last trading period, Marsh & McLennan closed at $163.01.
    • According to Deutsche Bank, the prior rating for Adient PLC (NYSE:ADNT) was changed from Buy to Hold. In the fourth quarter, Adient showed an EPS of $0.53, compared to $0.24 from the year-ago quarter. The stock has a 52-week-high of $50.96 and a 52-week-low of $27.15. At the end of the last trading period, Adient closed at $38.37.
    • Chardan Capital downgraded the previous rating for Oyster Point Pharma Inc (NASDAQ:OYST) from Buy to Neutral. In the second quarter, Oyster Point Pharma showed an EPS of $1.87, compared to $0.85 from the year-ago quarter. The current stock performance of Oyster Point Pharma shows a 52-week-high of $18.30 and a 52-week-low of $3.46. Moreover, at the end of the last trading period, the closing price was at $11.57.
    • B of A Securities downgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE:RBA) from Buy to Neutral. In the third quarter, Ritchie Bros Auctioneers showed an EPS of $0.53, compared to $0.45 from the year-ago quarter. The current stock performance of Ritchie Bros Auctioneers shows a 52-week-high of $72.73 and a 52-week-low of $48.65. Moreover, at the end of the last trading period, the closing price was at $51.29.
    • For Ouster Inc (NYSE:OUST), Baird downgraded the previous rating of Outperform to Neutral. In the third quarter, Ouster showed an EPS of $0.20, compared to $0.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.54 and a 52-week-low of $0.76. Ouster closed at $1.21 at the end of the last trading period.
    • Wedbush downgraded the previous rating for Williams-Sonoma Inc (NYSE:WSM) from Outperform to Neutral. In the second quarter, Williams-Sonoma showed an EPS of $3.87, compared to $3.24 from the year-ago quarter. The current stock performance of Williams-Sonoma shows a 52-week-high of $176.89 and a 52-week-low of $101.58. Moreover, at the end of the last trading period, the closing price was at $123.47.
    • According to Raymond James, the prior rating for ICU Medical Inc (NASDAQ:ICUI) was changed from Outperform to Market Perform. In the third quarter, ICU Medical showed an EPS of $1.75, compared to $2.07 from the year-ago quarter. At the moment, the stock has a 52-week-high of $251.73 and a 52-week-low of $132.75. ICU Medical closed at $142.07 at the end of the last trading period.
    • According to Deutsche Bank, the prior rating for Jack In The Box Inc (NASDAQ:JACK) was changed from Buy to Hold. In the third quarter, Jack In The Box showed an EPS of $1.38, compared to $1.79 from the year-ago quarter. The stock has a 52-week-high of $96.87 and a 52-week-low of $54.80. At the end of the last trading period, Jack In The Box closed at $86.07.
    • Piper Sandler downgraded the previous rating for Q2 Holdings Inc (NYSE:QTWO) from Neutral to Underweight. Q2 Holdings earned $0.10 in the third quarter, compared to $0.03 in the year-ago quarter. The current stock performance of Q2 Holdings shows a 52-week-high of $81.56 and a 52-week-low of $25.53. Moreover, at the end of the last trading period, the closing price was at $26.44.
    • For Benefitfocus Inc (NASDAQ:BNFT), Keybanc downgraded the previous rating of Overweight to Sector Weight. For the third quarter, Benefitfocus had an EPS of $0.12, compared to year-ago quarter EPS of $0.19. At the moment, the stock has a 52-week-high of $13.05 and a 52-week-low of $5.68. Benefitfocus closed at $10.40 at the end of the last trading period.
    • According to Piper Sandler, the prior rating for Oyster Point Pharma Inc (NASDAQ:OYST) was changed from Overweight to Neutral. For the second quarter, Oyster Point Pharma had an EPS of $1.87, compared to year-ago quarter EPS of $0.85. The stock has a 52-week-high of $18.30 and a 52-week-low of $3.46. At the end of the last trading period, Oyster Point Pharma closed at $11.57.
    • For Q2 Holdings Inc (NYSE:QTWO), RBC Capital downgraded the previous rating of Outperform to Sector Perform. Q2 Holdings earned $0.10 in the third quarter, compared to $0.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $81.56 and a 52-week-low of $25.53. Q2 Holdings closed at $26.44 at the end of the last trading period.
    • For Arcosa Inc (NYSE:ACA), Stephens & Co. downgraded the previous rating of Overweight to Equal-Weight. Arcosa earned $0.70 in the third quarter, compared to $0.57 in the year-ago quarter. The stock has a 52-week-high of $65.80 and a 52-week-low of $43.42. At the end of the last trading period, Arcosa closed at $59.32.
    • According to Evercore ISI Group, the prior rating for Lyft Inc (NASDAQ:LYFT) was changed from Outperform to In-Line. For the third quarter, Lyft had an EPS of $0.10, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $46.64 and a 52-week-low of $10.82. At the end of the last trading period, Lyft closed at $14.14.
    • Jefferies downgraded the previous rating for Six Flags Entertainment Corp (NYSE:SIX) from Buy to Hold. In the second quarter, Six Flags Entertainment showed an EPS of $0.68, compared to $0.81 from the year-ago quarter. The stock has a 52-week-high of $47.24 and a 52-week-low of $16.83. At the end of the last trading period, Six Flags Entertainment closed at $21.16.
    • Jefferies downgraded the previous rating for IAA Inc (NYSE:IAA) from Buy to Hold. IAA earned $0.45 in the third quarter, compared to $0.52 in the year-ago quarter. The current stock performance of IAA shows a 52-week-high of $51.12 and a 52-week-low of $31.32. Moreover, at the end of the last trading period, the closing price was at $38.42.

    See all analyst ratings downgrades.

     

    Initiations

    • Deutsche Bank initiated coverage on Planet Labs PBC (NYSE:PL) with a Buy rating. The price target for Planet Labs is set to $7.00. Planet Labs earned $0.15 in the second quarter, compared to $0.46 in the year-ago quarter. The current stock performance of Planet Labs shows a 52-week-high of $7.51 and a 52-week-low of $3.70. Moreover, at the end of the last trading period, the closing price was at $5.40.
    • Deutsche Bank initiated coverage on BlackSky Technology Inc (NYSE:BKSY) with a Buy rating. The price target for BlackSky Technology is set to $3.00. In the third quarter, BlackSky Technology showed an EPS of $0.11, compared to $0.67 from the year-ago quarter. The stock has a 52-week-high of $5.01 and a 52-week-low of $1.00. At the end of the last trading period, BlackSky Technology closed at $1.80.
    • Raymond James initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR) with a Market Perform rating. For the third quarter, Kymera Therapeutics had an EPS of $0.79, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $65.44 and a 52-week-low of $13.15. Kymera Therapeutics closed at $29.04 at the end of the last trading period.
    • For ASML Holding NV (NASDAQ:ASML), Morgan Stanley initiated coverage, by setting the current rating at Overweight. In the third quarter, ASML Holding showed an EPS of $4.32, compared to $5.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $799.36 and a 52-week-low of $363.15. ASML Holding closed at $483.39 at the end of the last trading period.
    • With a Buy rating, Canaccord Genuity initiated coverage on Passage Bio Inc (NASDAQ:PASG). The price target seems to have been set at $8.00 for Passage Bio. For the second quarter, Passage Bio had an EPS of $0.73, compared to year-ago quarter EPS of $0.90. The stock has a 52-week-high of $6.55 and a 52-week-low of $1.15. At the end of the last trading period, Passage Bio closed at $1.20.
    • Canaccord Genuity initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ:RCKT) with a Buy rating. The price target for Rocket Pharmaceuticals is set to $53.00. In the third quarter, Rocket Pharmaceuticals showed an EPS of $0.87, compared to $0.79 from the year-ago quarter. The current stock performance of Rocket Pharmaceuticals shows a 52-week-high of $24.18 and a 52-week-low of $7.57. Moreover, at the end of the last trading period, the closing price was at $16.24.
    • With a Buy rating, Canaccord Genuity initiated coverage on Generation Bio Co (NASDAQ:GBIO). The price target seems to have been set at $9.00 for Generation Bio. For the third quarter, Generation Bio had an EPS of $0.53, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $9.59 and a 52-week-low of $3.96. Generation Bio closed at $6.47 at the end of the last trading period.
    • Canaccord Genuity initiated coverage on Tenaya Therapeutics Inc (NASDAQ:TNYA) with a Buy rating. The price target for Tenaya Therapeutics is set to $21.00. Tenaya Therapeutics earned $0.69 in the second quarter, compared to $13.26 in the year-ago quarter. The stock has a 52-week-high of $19.45 and a 52-week-low of $1.90. At the end of the last trading period, Tenaya Therapeutics closed at $1.92.
    • JonesTrading initiated coverage on HCW Biologics Inc (NASDAQ:HCWB) with a Buy rating. The price target for HCW Biologics is set to $8.00. HCW Biologics earned $0.11 in the third quarter, compared to $0.14 in the year-ago quarter. At the moment, the stock has a 52-week-high of $3.32 and a 52-week-low of $1.76. HCW Biologics closed at $2.28 at the end of the last trading period.
    • With a Buy rating, Canaccord Genuity initiated coverage on Taysha Gene Therapies Inc (NASDAQ:TSHA). The price target seems to have been set at $16.00 for Taysha Gene Therapies. In the third quarter, Taysha Gene Therapies showed an EPS of $0.64, compared to $1.35 from the year-ago quarter. The current stock performance of Taysha Gene Therapies shows a 52-week-high of $12.17 and a 52-week-low of $1.35. Moreover, at the end of the last trading period, the closing price was at $2.00.

    See all analyst ratings initiations.

    Get the next $ACA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACA
    $ADNT
    $ASML
    $AVEO

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Viatris Inc.
    $VTRS
    2/9/2026$18.00Neutral → Buy
    UBS
    Adient plc
    $ADNT
    2/5/2026$33.00Hold → Buy
    Deutsche Bank
    Q2 Holdings Inc.
    $QTWO
    2/3/2026$82.00Neutral → Buy
    DA Davidson
    ASML Holding N.V. New York Registry Shares
    $ASML
    1/29/2026Equal Weight → Overweight
    Barclays
    Kymera Therapeutics Inc.
    $KYMR
    1/28/2026$133.00Overweight
    Barclays
    National Storage Affiliates Trust
    $NSA
    1/26/2026Underperform → Peer Perform
    Wolfe Research
    Southern Copper Corporation
    $SCCO
    1/23/2026$117.50Neutral → Underweight
    Analyst
    More analyst ratings

    $ACA
    $ADNT
    $ASML
    $AVEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Gary B bought $313 worth of shares (20 units at $15.66) and sold $254 worth of shares (20 units at $12.69) (SEC Form 4)

    4 - Planet Labs PBC (0001836833) (Issuer)

    2/3/26 6:35:28 PM ET
    $PL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    SVP, Chief Legal Officer Rodriguez Rodolfo Jr bought $14,673 worth of shares (730 units at $20.10), increasing direct ownership by 5% to 14,500 units (SEC Form 4)

    4 - Dave & Buster's Entertainment, Inc. (0001525769) (Issuer)

    1/20/26 4:30:17 PM ET
    $PLAY
    Restaurants
    Consumer Discretionary

    Director Bjork Elisabeth bought $34,400 worth of shares (10,000 units at $3.44), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    1/6/26 4:05:11 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACA
    $ADNT
    $ASML
    $AVEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adient upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Adient from Hold to Buy and set a new price target of $33.00

    2/5/26 6:50:02 AM ET
    $ADNT
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ACA
    $ADNT
    $ASML
    $AVEO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC

    Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling

    5/17/23 4:40:03 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    FDA Approval for TYRVAYA issued to OYSTER POINT PHARMA INC

    Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form

    10/19/21 7:27:01 PM ET
    $OYST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/29/21 5:44:34 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACA
    $ADNT
    $ASML
    $AVEO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    2/13/26 5:32:39 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by IREN Limited

    SCHEDULE 13G/A - IREN Ltd (0001878848) (Subject)

    2/13/26 5:14:55 PM ET
    $IREN
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Mettler-Toledo International Inc.

    SCHEDULE 13G - METTLER TOLEDO INTERNATIONAL INC/ (0001037646) (Subject)

    2/13/26 4:29:59 PM ET
    $MTD
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACA
    $ADNT
    $ASML
    $AVEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Israel Joseph covered exercise/tax liability with 2,826 shares, decreasing direct ownership by 5% to 51,534 units (SEC Form 4)

    4 - Delek US Holdings, Inc. (0001694426) (Issuer)

    2/13/26 9:22:00 PM ET
    $DK
    Integrated oil Companies
    Energy

    New insider Maletta Matthew Joseph claimed ownership of 25 shares (SEC Form 3)

    3 - Viatris Inc (0001792044) (Issuer)

    2/13/26 6:01:22 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hagedorn Partnership, L.P. sold $3,319,935 worth of shares (50,000 units at $66.40) (SEC Form 4)

    4 - SCOTTS MIRACLE-GRO CO (0000825542) (Issuer)

    2/13/26 4:37:30 PM ET
    $SMG
    Agricultural Chemicals
    Industrials

    $ACA
    $ADNT
    $ASML
    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

    HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics' TRBC drug development platform Initiation of Phase 1 clinical study expected in the first half of 2027 HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory MIRAMAR, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflamm

    2/13/26 8:30:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shareholders Cannot Afford to Allow Chairman David Goebel to Remain as a Director at Jack in the Box – Asserts Biglari Capital

    SAN ANTONIO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Biglari Capital Corp. ("Biglari Capital"), the largest shareholder of Jack in the Box Inc. (NASDAQ:JACK), with a 9.86% ownership stake, today issued the following statement in response to JACK's latest shareholder letter: David Goebel's 17 Years of Failure Cannot Be Disguised as "Expertise" David Goebel has had 17 years to prove that his restaurant experience benefits JACK's shareholders. Instead, shareholders have lost approximately $1.8 billion — or 80% of the company's value — in the last five years alone.JACK now claims Mr. Goebel is "one of the most qualified franchise executives" in the industry. If that is true, why has he consist

    2/13/26 7:38:17 AM ET
    $JACK
    Restaurants
    Consumer Discretionary

    Planet Convenes European and Defense Advisory Boards

    New boards will support the company's strategic expansion across Europe and enhance opportunities between Planet and global security partners Planet Labs PBC (NYSE:PL), a leading provider of daily data and insights about change on Earth, today announced at the 2026 Munich Security Conference the formation of two world-class advisory bodies: its European Advisory Board and Defense and Intelligence (D&I) Advisory Board. Composed of global leaders with renowned government, military, and diplomatic expertise, the development of this preeminent bench of advisors underscores Planet's deepening commitment to serving a diverse global customer base, specifically focusing on strategic partnership

    2/13/26 2:47:00 AM ET
    $PL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ACA
    $ADNT
    $ASML
    $AVEO
    Leadership Updates

    Live Leadership Updates

    View All

    Jack in the Box Inc. Reiterates Confidence in David Goebel-Led Board of Directors in Overseeing Successful Execution of "JACK on Track" Plan

    Highlights Biglari's Self-Interested Campaign and Contradictory and Volatile Behavior that Hindered the Board's Attempts at Constructive Engagement Urges Shareholders to Vote "FOR" all 10 of Jack in the Box's Director Nominees, including David Goebel, Independent Chair of the Jack in the Box Board, on the WHITE Proxy Card Visit www.KeepJackonTrack.com for More Information Jack in the Box Inc. ("Jack in the Box" or the "Company") (NASDAQ:JACK), today mailed a letter to shareholders in connection with its upcoming Annual Meeting of Shareholders scheduled to be held on February 27, 2026 (the "Annual Meeting"). Shareholders of record as of January 2, 2026, will be entitled to vote at the

    2/10/26 8:00:00 AM ET
    $JACK
    Restaurants
    Consumer Discretionary

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ACA
    $ADNT
    $ASML
    $AVEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    12/4/24 2:38:58 PM ET
    $LYFT
    Real Estate

    $ACA
    $ADNT
    $ASML
    $AVEO
    Financials

    Live finance-specific insights

    View All

    Shareholders Cannot Afford to Allow Chairman David Goebel to Remain as a Director at Jack in the Box – Asserts Biglari Capital

    SAN ANTONIO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Biglari Capital Corp. ("Biglari Capital"), the largest shareholder of Jack in the Box Inc. (NASDAQ:JACK), with a 9.86% ownership stake, today issued the following statement in response to JACK's latest shareholder letter: David Goebel's 17 Years of Failure Cannot Be Disguised as "Expertise" David Goebel has had 17 years to prove that his restaurant experience benefits JACK's shareholders. Instead, shareholders have lost approximately $1.8 billion — or 80% of the company's value — in the last five years alone.JACK now claims Mr. Goebel is "one of the most qualified franchise executives" in the industry. If that is true, why has he consist

    2/13/26 7:38:17 AM ET
    $JACK
    Restaurants
    Consumer Discretionary

    Global Partners LP to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on February 27, 2026

    Global Partners LP (NYSE:GLP) ("Global Partners" or the "Partnership") today announced that it will release its fourth-quarter and full-year 2025 financial results before the market opens on Friday, February 27, 2026. At 10:00 a.m. ET, the Partnership will conduct a conference call for investors and analysts hosted by Eric Slifka, President and Chief Executive Officer, Gregory B. Hanson, Chief Financial Officer, and Mark Romaine, Chief Operating Officer. The call can be accessed by dialing (877) 709-8155 (U.S. and Canada) or (201) 689-8881 (International). The live and archived audio replay of the conference call can be accessed by visiting the "Events & Presentations" section of the "Inv

    2/12/26 8:30:00 AM ET
    $GLP
    Oil Refining/Marketing
    Energy

    Ballard Announces Q4 and Full Year 2025 Results Conference Call

    VANCOUVER, BC, Feb. 11, 2026 /CNW/ - Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) will hold a conference call on Thursday, March 12th, 2026 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to review fourth quarter and full year 2025 operating results. The live call can be accessed by dialing +1-833-821-2814 (Canada/US toll free). Alternatively, a live webcast can be accessed through a link on Ballard's homepage (www.ballard.com). Following the call, a link to the webcast will be available in the 'Investor Hub' area of the 'Investors' section of Ballard's website (www.ball

    2/11/26 8:00:00 PM ET
    $BLDP
    Industrial Machinery/Components
    Energy